Until recently the most common autoinflammatory diseases (AIDs) associated with bone disease in childhood included a few genetically complex (chronic non-bacterial osteomyelitis, synovitis, acne, pustulosis, hyperostosis and osteitis syndrome) and monogenic (Majeed syndrome, deficiency of IL-1 receptor antagonist, cherubism) AIDs. However, the spectrum of monogenic AIDs associated with bone manifestations has markedly expanded to include both recently identified diseases such as the type I interferonopathies and also newly recognized bone dysplasias in already established AIDs. In addition, we propose that some known bone dysplasia syndromes, especially those presenting with hyperostosis and associated systemic inflammation, be classified as AIDs. Collectively, we provide an overview of the diverse bone manifestations identified in the genetically defined AIDs, discuss the hypotheses of the underlying pathophysiological mechanisms and highlight potential novel therapeutic strategies.
Introduction
Autoinflammatory diseases (AIDs) are immune dysregulatory conditions mediated by cells of the innate immune system, such as neutrophils and macrophages, without the usual features of autoimmunity (high-titre autoantibodies and antigen-specific T cells) [1, 2] . They typically present with chronic and recurrent bouts of systemic inflammation and are variably associated with the involvement of various organs and tissues, including skin, joints and muscles, lungs, CNS and also bones. All previous reviews on AIDs with bone manifestations focused on a few genetically complex AIDs such as chronic recurrent multifocal osteomyelitis (CRMO); synovitis, acne, pustulosis, hyperostosis and osteitis syndrome and some monogenic AIDs such as Majeed syndrome; deficiency of IL-1 receptor antagonist (DIRA); pyogenic arthritis, pyoderma gangrenosum and acne (PAPA); and cherubism [36] . However, with time, the spectrum of monogenic AIDs with bone manifestations has markedly expanded to include both recently identified AIDs, especially the interferonopathies [7] , and new descriptions of bone dysplasia in known AIDs [8] . In addition, some known bone dysplasia syndromes, especially bone disorders presenting with hyperostosis accompanied by systemic inflammation, may be considered as AIDs. In this review we provide an overview of the current genetically defined AIDs associated with bone involvement and discuss the hypotheses of pathogenic mechanisms and potential novel therapeutic targets of these bone manifestations.
Bone involvement associated with IL-1-mediated monogenic AIDs A number of rare monogenic AIDs are characterized by increased activation of IL-1 signalling pathways leading to increased secretion of IL-1b. Four of these conditions [chronic infantile neurologic, cutaneous and articular (CINCA) syndrome, DIRA, Majeed syndrome and PAPA) display different and distinct types of bone involvement (Tables 1 and 2 ).
Cryopyrin-associated periodic syndrome
Cryopyrin-associated periodic syndrome (CAPS) [Online Mendelian Inheritance in Man (OMIM) 607115] comprises three overlapping autoinflammatory conditions, including familial cold autoinflammatory syndrome, MuckleWells syndrome and neonatal-onset multisystem inflammatory disorder (NOMID/CINCA). Clinical features include early onset rash, conjunctivitis, arthritis, chronic meningitis, sensorineural deafness and intellectual impairment [9] . Systemic amyloid A (AA) amyloidosis develops in 25% of patients. Cryopyrin-associated periodic syndrome is associated with gain-of-function mutations in NLRP3, the gene encoding cryopyrin, a component of the IL-1 inflammasome regulating the production of IL-1b, a key pro-inflammatory cytokine. Germline NLRP3 mutations are identified in only 60% of patients with a clinical CAPS phenotype, suggesting a role for as yet unidentified genes, NLRP3 somatic mosaicism [10] or deep intronic mutations not found by exon sequencing. Among 136 patients included in the Eurofever Registry, 31 different NLRP3 mutations were recorded. Some very rare NLRP3 variants were significantly associated with severe musculoskeletal involvement [11] .
Bone involvement includes two types of manifestations: (i) a specific severe patellar, epiphyseal and metaphyseal hypertrophy resulting from enchondral bone formation predominantly involving the knees and reported in 1433% of patients with CINCA syndrome (Fig. 1A ) [11] and (ii) non-specific cartilage/bone lesions resulting from severe inflammatory polyarthritis. Structural damage with erosions and joint space narrowing of the hands and wrists and erosions at the Achilles tendon insertion may develop during follow-up in patients with CAPS-related arthritis [11] .
The pivotal pathogenic role of IL-1 in CAPS has been underlined by the achievement of complete remission using anti-IL-1 agents, recombinant human IL-1 receptor antagonist (anakinra) and monoclonal anti-IL-1b (canakinumab) [1214] . IL-1 antagonism controls inflammatory arthritis with stabilization or slow progression of metaphyseal and epiphyseal abnormalities. However, bony overgrowth does not improve with treatment [11, 12] .
Pro-inflammatory cytokines such as IL-1b, IL-6 and TNF-a have been shown to have dual negative effects on bone homeostasis in vitro and in vivo [15, 16] . While bone formation is the function of osteoblasts, bone resorption is the main function of osteoclasts, haematopoietic cells of the monocyte/macrophage lineage. The differentiation, survival and activity of osteoclasts relies on the expression of RANK ligand (RANKL) on osteoblasts, a TNF family member. TNF-a and b interact closely to enhance bone resorption through direct activation of osteoclastogenesis or by expression of RANKL and M-CSF in stromal cells [16, 17] . In addition, both cytokines can interfere with bone formation and osteoblast differentiation [17, 18] .
Since constitutively increased IL-1b secretion is characteristic of CAPS, it may be hypothesized that Il-1b has a role in CINCA-related bone loss and erosive bone lesions. Conversely bony overgrowth is observed only in a small proportion of patients with IL-1b-mediated monogenic diseases and does not improve with anti-IL-1 agents, which suggests that other mechanisms are involved in the pathogenesis of distinct bone hypertrophy lesions. A high level of expression of NLRP3 is restricted to polymorphonuclear cells and chondrocytes [19] , suggesting that CINCA-associated mutations may directly affect cartilage homeostasis and growth. CINCA mice exhibit growth retardation and severe postnatal osteopenia stemming at least in part from abnormally increased osteoclastogenesis [20] . Histopathology of knee joints revealed abnormal growth plates, with a loss of chondrocytes and growth arrest in the central region of the epiphyses, as well as massive leucocyte infiltration in the adjacent joints. Most strikingly, a tissue spike was observed in the mid-region of the growth plate in the long bones of all CINCA mice that may be the precursor of more severe deformations analogous to those observed in CINCA patients. These findings provide evidence for linking CINCAassociated mutations to abnormalities of postnatal skeletal growth and bone remodelling [20] . Yokoyama et al. [21] showed through generation of induced pluripotent stem cells (iPSCs) that the epiphyseal overgrowth by chondrocytes seen in CINCA patients is dependent on the cyclic adenosine monophosphate (cAMP)/protein kinase A/cAMP response element binding protein pathway for the upregulation of SOX9 mRNA in a mutant NLRP3-dependent manner. The addition of NLRP3 component inhibitors did not prevent the formation of large cartilaginous masses in culture, mirroring what is seen in CINCA patients with anti-IL-1b treatment.
Monogenic CRMO: DIRA, Majeed syndrome and CRMO related to FBLIM1 mutation Deficiency of IL-1 receptor antagonist (OMIM 612852) is a severe autosomal recessive AID with prominent involvement of skin and bone with onset in the perinatal period [22] . The condition is caused by mutations affecting IL1RN, encoding the IL-1-receptor antagonist. Mutations lead to IL-1 receptor antagonist deficiency due to either large homozygous genomic deletions or homozygous or compound heterozygous nonsense mutations [22, 23] . Other mutations lead to the expression of a non-functional protein. Collectively, these cause unopposed signalling through the IL-1 receptor with hyperresponsiveness of cells to IL-1a and IL-1b and overproduction of a host of inflammatory cytokines, chemokines and other mediators [2] .
Typically, patients present with marked pain, periarticular swelling and mild to severe pustulosis without fever. If untreated, lung and CNS manifestations may follow and a fatal course can ensue. Characteristic radiographic findings are balloonlike epiphyseal widening of the anterior rib ends, multifocal osteolytic lesions and periosteal reaction along multiple long bones. Less common is heterotopic ossification of the proximal femurs, widening of the clavicles and metaphyseal erosions of the long bones [22] . Collapse of the vertebrae due to osteolytic lesions can occur. Systemic inflammatory markers were elevated in all patients and bone biopsy revealed a sterile purulent osteomyelitis with fibrosis and sclerosis [22] . Bone, skin and systemic manifestations resolved promptly upon initiation of treatment with anakinra in all reported patients [22, 23] . This emphasizes the prominent role of IL-1 in the development of bone manifestations in affected patients, although the exact pathophysiology of bone lesions remains to be elucidated.
Majeed syndrome
Majeed syndrome (OMIM 609628) is a syndromic, early onset form of CRMO with congenital dyserythropoietic anaemia. The anaemia is a hypochromic, microcytic form and presents in the first year of life with variable severity from mild to transfusion dependent [2426] . Bone disease is characterized by attacks of fever, severe bone pain and soft tissue swelling typically around large joints. A minority of patients develop neutrophilic dermatosis (Sweet's syndrome) and heterozygous carriers may have psoriasis [23] . Skeletal radiographs show irregular osteolytic (radiolucent) lesions with surrounding sclerosis, usually in the metaphyses of the long bones. Hyperostosis may be present in clavicular lesions [27] . On MRI, active bone lesions show increased signal intensity on T 2 -weighted and short tau inversion recovery images and decreased signal intensity on T 1 -weighted images [27] . The disease is due to autosomal recessive mutations in LPIN2, which encodes lipin-2, a phosphatidate phosphatase important in lipid metabolism in mice. Loss of lipin-2 activity in human and murine monocytic cells results in inflammatory responses to exogenous fatty acids, including the hyperproduction of pro-inflammatory cytokines [2] . These findings suggest that an abnormal innate immune system response to fatty acids might play a role in the pathogenesis of Majeed syndrome and its associated inflammatory bony lesions.
Majeed osteitis is treated with NSAIDs and physical therapy. In the absence of response to NSAIDs, a short course of corticosteroids can be initiated. Two affected children had resolution of their systemic and bone inflammation when treated with an IL-1 inhibitor, which supports the hypothesis that IL-1 is important in bone disease pathogenesis [27] . Conversely, the effect on the anaemia was less clear since bone marrow biopsies have not been performed after treatment initiation.
DIRA and Majeed syndrome represent monogenic forms of CRMO, which is mostly known as a sporadic condition, and share several pathomechanisms. Non-syndromic CRMO is the most common autoinflammatory bone disease. It is a non-infectious multifocal osteitis affecting children and adolescents. Bone lesions tend to cluster around the metaphyses of the long bones and often have a symmetric distribution; typical radiographic findings include osteolytic lesions at the metaphysis that progress to sclerosis or hyperostosis. In the early stages, neutrophils are the predominant infiltrating cells, with monocytes, macrophages, lymphocytes and plasma cells being detected during later stages of the disease. Additional organs can be involved, including the skin, eyes, gastrointestinal system and lungs. Skin inflammation can manifest as palmoplantar pustulosis, psoriasis and occasionally as pyoderma gangrenosum.
There is evidence for a genetic basis of CRMO, and homozygous mutations in FBLIM1 have been recently identified in two patients with non-syndromic CRMO [28] . FBLIM1 encodes filamin-binding LIM protein 1 or migfilin, a filamin-binding protein involved in the regulation of bone remodelling Bone inflammation in DIRA and Majeed syndrome is histologically similar to bone inflammation seen in CRMO. However, it is only part of a symptom complex in familial CRMO, whereas it is the unique defining feature in sporadic CRMO. IL-1b was found to be a critical cytokine in the pathogenesis of osteomyelitis in the chronic multifocal osteomyelitis (cmo) mouse, which is affected by a disease that is phenotypically similar to CRMO resulting from missense mutation (L98P) of proline-serinethreonine phosphatase-interacting protein (Pstpip2) [29] . Deficiency of IL-1 receptor type I in cmo mice resulted in a significant delay in onset of the disease as well as a reduced degree of bone pathology. Conversely, inflammatory bone disease was found to be independent of the NLRP3 inflammasome as well as caspase-1. Neutrophils from cmo mice showed increased IL-1b production in response to adenosine triphosphate, silica and Pseudomonas aeruginosa, which was sensitive to inhibition by serine protease inhibitors. The authors concluded there is an inflammasome-independent role for IL-1b in disease progression of cmo and a role for neutrophils and neutrophil serine proteases in disease pathogenesis [29, 30] . Taken together, the improvement of the two syndromic forms of human CRMO under IL-1 blockade and data generated in the Pstpip2-deficient cmo mice identify IL-1b as the key disease-associated cytokine, although the precise link between osteitis and IL-1b remains to be elucidated. The precise pathophysiology of CRMO remains unknown. However, recent data suggest that mutations in FBLIM1 could lead to the chronic inflammation and bone lesions characteristic of CRMO by enhancing osteoclastogenesis and diminishing osteoblastogenesis, resulting in excessive bone resorption in a few CRMO patients [28] .
PAPA
PAPA presents with recurrent episodes of sterile pyogenic arthritis during childhood associated with neutrophilic skin lesions ranging from cystic acne to pyoderma gangrenosum. The arthritis is erosive and often progresses to bone destruction and ankylosis necessitating joint replacement therapy during the course of PAPA [31, 32] . PAPA is an autosomal dominant disease resulting from mutations in threonine. The PAPA-causing mutations in PSTPIP1 result in hyperphosphorylation of the mutated protein and increased avidity for pyrin. This binding may release pyrin from its autoinhibition, causing an increase in the pyrin domain of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) pyroptosome assembly leading to pro-caspase 1 recruitment and activation, thereby resulting in overproduction of IL-1b.
IL-1b and TNF-a targeted therapies have provided a generally superior alternative to high-dose corticosteroids in relieving inflammatory flares of PAPA syndrome. However, these biologics have not been consistently effective in all cases and do not necessarily suppress all disease manifestations, suggesting the involvement of other pro-inflammatory cytokines such as IL-18, which is also activated by the inflammasome [33, 34] .
Hyperphosphatemic familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome: a possible IL-1-mediated disease?
Familial tumoral calcinosis (FTC) (OMIM 211900) is a rare disorder caused by mutations in three different genes: fibroblast growth factor 23 (FGF23), encoding a potent phosphaturic hormone; GALNT3, encoding a glycosyltransferase responsible for initiating mucin-type O-glycosylation, or KL (Klotho), encoding an FGF23 co-factor required for activation of FGF receptors. Mutations in the GALNT3 gene are also responsible for hyperostosishyperphosphatemia syndrome (HHS) (OMIM 610233). Thus FTC and HHS represent a continuous spectrum of the same disease, rather than two distinct disorders caused by increased phosphate levels [35] . The result of these mutations is functional deficiency of or resistance to intact FGF23 (iFGF23), causing hyperphosphatemia, increased renal tubular reabsorption of phosphorus and elevated or inappropriately normal 1,25-dihydroxyvitamin D 3 [1,25(OH) 2 D] . Clinical manifestations range from asymptomatic to large, disabling calcifications, typically periarticular and of various sizes in multiple locations. Radiographs show cortical hyperostosis, diaphysitis and periosteal apposition (HHS) and/or periarticular calcifications (FTC) (Fig. 1E) . Severe vascular, eyelid and bowel calcifications may also occur [36] . Histologic analyses show ectopic calcifications against a background of chronic inflammation with multiple foamy macrophages.
In addition to calcifications and hyperostosis, some patients share an autoinflammatory phenotype with intermittent fever and local inflammation, pain and tender swelling over the long bones, elevated CRP and ESR, anaemia and chronic thrombocytosis [35, 36] . In two patients, anti-IL-1 agents improved the biological and/or clinical manifestations [36] . CRP levels normalized and painful erythematous calcinosis cutis resolved on canakinumab therapy in one patient while a short course of anakinra decreased CRP levels in another patient. These features suggest that FRC/HHS may be considered within the spectrum of AIDs and might be an IL-1b-mediated disease, also because it shares some distinct bone manifestations (periostitis, ectopic calcifications) with DIRA.
To summarize, increased IL-1b secretion is associated with various bone manifestations that differ according to the underlying genetic defect. They comprise either specific manifestations such as non-infectious osteomyelitis (DIRA, Majeed syndrome), bone overgrowth (CINCA arthropathy), periostitis and heterotopic ossification (DIRA and possibly hyperphosphatemic FTC) or non-specific inflammatory erosive arthritis and bone destruction (CINCA and PAPA) (Fig. 2) . IL-1 is a potent stimulator of bone resorption in vitro and in vivo since it enhances osteoclast precursor fusion and osteoclast survival in vitro [37] . Thus the occurrence of erosive bone disease in inflammatory arthritis may be explained by the IL-1b-induced activation of osteoclasts. The critical role of IL1b in some specific bone manifestations is demonstrated by the occurrence of non-infectious osteitis in cmo mice and by the loss of chondrocytes and growth arrest in the central region of the epiphyses in the CINCA mice. Finally, anti-IL-1 agents efficiently treat most of the bone manifestations associated with IL-1-mediated monogenic AIDs, except for CAPS-associated bony overgrowth. In addition, the use of these agents may be evaluated for the treatment of hyperphosphatemic FTC. Conversely, the heterogeneity of IL-1b-related bone diseases indicates that additional mediators and/or pathways are probably involved in the pathogenesis of the various bone manifestations seen in IL-1-mediated AIDs.
Bone involvement associated with IFN type Imediated monogenic AIDs
Interferonopathies are a group of Mendelian conditions characterized by excessive type I IFN production resulting from either inappropriate stimulation or defective negative regulation of the type I IFN response pathway [38] . AicardiGoutiè res syndrome, a condition characterized by inflammatory encephalomyelitis and basal ganglia calcifications, was the first Mendelian disease linked to an upregulation of IFN-stimulated genes [39] . With time, the spectrum of Mendelian interferonopathies includes a growing number of other inflammatory conditions, some of them associated with bone involvement.
Spondylenchondrodysplasia
Spondylenchondrodysplasia (SPENCD; OMIM 271550) is a skeletal dysplasia characterized by radiolucent metaphyseal and vertebral lesions [38, 39] . Bone manifestations are the hallmark of the disease. Enchondromas predominantly develop within the long bones but may also occur in other areas of endochondral growth [38] . Characteristic skeletal manifestations consist of platyspondyly (Fig. 1B1) and/or metaphyseal dysplasia. The severity of the lesions varies, but slow progression during childhood is frequently observed, resulting in significant short stature. The skeletal phenotype is variable, with stature from within the normal range to 6.5 S.D. below the mean. Short stature is due to a short trunk and/or short limbs depending upon the relative degree of spinal and/or long bone dysplasia. A number of patients also manifest specific skeletal deformities, including short distal phalanges (Fig. 1B2) , kyphosis and pectus carinatum [38] . BMD is normal or increased without evidence of osteopetrosis. Extra-osseous manifestations reported in SPENCD are mostly neurological, including developmental delay and spasticity, which may be associated with intracranial calcification. Autoimmune disease was subsequently recognized as a prominent feature, with at least one autoimmune feature present in 85% of patients in the recent series of Briggs et al. [40] . The most common autoimmune manifestations were autoimmune thrombocytopenic purpura (50%) and SLE (27%). SPENCD-related immunodeficiency has been suggested by the occurrence of recurrent bacterial and viral infections in some patients [40] .
SPENCD is caused by biallelic mutations in ACP5, encoding tartrate-resistant acid phosphatase (TRAP) [38, 39] . Affected individuals display an absence of TRAP serum expression, increased levels of serum IFN-a and an upregulation of IFN-stimulated genes, endorsing the inclusion of SPENCD within type I interferonopathies. TRAP is a lysosomal enzyme expressed in differentiated cells of monohistiocytic lineage, including osteoclasts as well as dendritic cells and macrophages, explaining the involvement of both the skeletal and immune systems in SPENCD patients. Osteopontin (Opn), which is dephosphorylated and thus deactivated by TRAP, may be implicated in the pathology of SPENCD [39] . Opn has been linked to IFN-a secretion in plasmatoid dendritic cells [41, 42] . In the absence of TRAP activity, phosphorylated Opn may accumulate, leading to IFN-a stimulation.
Skeletal abnormalities observed in homozygous ACP5 knockout mice suggest that TRAP has an essential role in endochondral ossification [43] . These mice have progressive foreshortening and deformity of the long bones and axial skeleton. The epiphyseal growth plates are widened, with delayed mineralization of cartilage. The columns of chondrocytes are disorganized and cells show marked hypertrophy and hyperplasia, with increased retention of thicker metaphyseal trabeculae and reduced modelling and mineralization of the expanded cartilaginous matrix. Abundant TRAP-negative osteoclasts invaded the epiphyseal plates within the disorganized region of remodelling. There was also increased mineralization caused by reduced osteoclast modelling activity [43] .
There is no specific treatment for SPENCD. Corticosteroids and immunosuppressive drugs are used to treat autoimmune manifestations but have no effect on bone involvement.
Stimulator of IFN genesassociated vasculopathy with onset in infancy
Stimulator of IFN genes (STING)-associated vasculopathy with onset in infancy (OMIM 615934) is characterized by neonatal-onset systemic inflammation with elevated ESR and CRP levels. It constitutes a severe cutaneous vasculopathy leading to extensive tissue loss and progressive interstitial lung disease. Some patients display bone resorption of the distal phalanges, carpal bone erosions and progressive ulnar deviation, which might result from articular inflammation [44] . Fibroblasts from patients did not show increased transcription of the genes encoding IL-1, IL-6 or TNF, pro-inflammatory cytokines regulating both RANKL expression and acting in synergy with this factor to propagate inflammation-associated bone erosion in inflammatory polyarthritis. Further studies are warranted to elucidate the mechanism of bone erosions in STING-associated vasculopathy with onset in infancy (SAVI).
SAVI results from gain-of-function mutations in TMEM173, the gene encoding STING, a key adaptor molecule that links the sensing of cytosolic DNA, derived from foreign triggers (i.e. viral and bacterial) or from self, to the production of IFNs. Patients with SAVI had an increased expression of IFN-stimulated gene transcripts in peripheral whole blood [44] .
Recently, three patients with recurrent fevers, destructive skin lesions and interstitial lung disease resulting from TMEM173-activating mutations were successfully treated with ruxolitinib, an oral Janus kinase 1/2 inhibitor [45] . None of them had bone involvement.
SingletonMertens
SingletonMertens (SMS; OMIM 182250) is an autosomal dominant disease characterized by abnormalities of blood vessels, teeth and bone [46, 47] . Bone manifestations include (i) osteoporosis (generalized or limited to distal extremities); (ii) osteolysis, especially distal limb osteolysis and early onset periodontal disease, resulting from severe root/alveolar bone resorption associated with dysregulated mineralization and ultimately teeth loss and (iii) widened medullary cavities. Other manifestations include calcifications of the aorta, aortic and mitral valves in childhood or puberty and dental abnormalities (delay in primary tooth exfoliation and permanent tooth eruption, truncated tooth root formation). Less commonly, unusual facial features (high anterior hair line, broad forehead, smooth philtrum and thin upper vermillion), generalized muscle weakness and joint laxity, psoriasis, early onset glaucoma and recurrent infections have been reported [48] . A gain-of-function IFIH1 (IFN induced with helicase C domain 1) mutation, encoding melanoma differentiationassociated protein 5 (MDA5) was identified as causing SMS. IFIH1 has also been linked to AicardiGoutiè res syndrome, and IFN signature genes were upregulated in SMS individuals' blood and dental cells [49] . MDA5 is a member of the retinoic acid-inducible gene Ilike receptor family and functions as a cytoplasmic pattern recognition receptor recognizing virus dsRNA and secreted bacterial nucleic acids. It is detected in cartilage chondrocytes and in active osteoblasts at the surface of the alveolar bone, suggesting that the mutated protein may be implicated in bone loss observed in SMS [46] .
In conclusion, the observed bone manifestations markedly differ according to the underlying disease and comprise abnormalities of BMD that may be either decreased (SMS) or increased (SPENCD); bone erosions that might be a consequence of inflammatory arthritis (STING) and bone resorption (STING, SMS) or a distinct bone dysplasia (SPENCD) ( Table 2 and Fig. 2 ). Type I IFNs inhibit osteoclast differentiation and IFN receptordeficient mice demonstrate enhanced osteoclastogenesis and a reduction of trabecular bone mass, a characteristic feature of osteoporosis [50] . Thus type I IFN might be directly responsible for the increase of BMD in SPENCD. Conversely, the inflammatory bone loss observed in SAVI and SMA syndrome may result from increased levels of other pro-inflammatory cytokines. This hypothesis is supported by the demonstration of increased transcription of genes encoding TNF and IL-6 in unstimulated peripheral blood mononuclear cells from SAVI patients [44] . Several drugs targeting the type I IFN pathway (Janus kinase 1/2 inhibitors) are currently being evaluated for treating interferonopathies such as SAVI, but their efficacy in controlling type I IFNmediated bone disease has not yet been assessed.
Bone involvement associated with nuclear factor kBmediated monogenic AIDs Blau syndrome is a unique autosomal dominant granulomatous autoinflammatory condition characterized by a clinical triad of granulomatous dermatitis, uveitis and polyarthritis starting at an early age. Blau arthritis affects peripheral small and large joints, is non-erosive and is associated with the development of limitations and deformities, especially camptodactyly, after several decades. Recently a number of bone morphological dysplastic-like changes have been documented in very young patients, increasing with prolonged disease duration. Major morphological alterations comprise a biconcave radial epiphysis, carpal dysplasia with carpal crowding (especially of the scaphoid and lunate bone), short plump ulnae and camptodactyly (proximal IP joint contracture) (Fig.1C) [51] .
Blau syndrome is caused by heterozygous missense mutations in the central nucleotide binding oligomerization domain containing receptor-interacting protein (RIP) (NOD)/ NACHT domain of NOD2, a cytosolic sensor for pathogenand danger-associated molecular patterns [52] . Blau syndrome NOD2 mutations lead to a constitutive activation of the NOD2 signalling pathway, causing activation of downstream RIP2 kinase and release of pro-inflammatory cytokines and chemokines.
The underlying mechanism for these changes is unclear at present. Although the dysplastic changes in Blau syndrome are epiphyseal rather than metaphyseal and less severe than those observed in CINCA/neonatal-onset multisystem inflammatory disorder syndrome, the fact that NOD2 shares structural and functional characteristics with NLRP3 [53] suggests that NOD2 may have a role in abnormal pathways in bone or cartilage morphogenesis [54] .
Bone involvement in monogenic AIDs associated with increased TNF-a production Cherubism Cherubism (OMIM 118400) is a skeletal dysplasia characterized by the appearance of symmetrical, multilocular, expansile radiolucent lesions of the mandible and/or the maxilla that typically appear at the age of 27 years. The severity of the disease is variable and grading systems have been suggested to describe the location and severity of the lesions [55] : grade 1, fibro-osseous bilateral and symmetrical expansions in the rami of the mandible; grade 2, more severe involvement of the ramus and body of the mandible and the tuberosity region of the maxillae; and grade 3, involvement of the entire maxilla and mandible with considerable facial deformity. Multiple radiolucent lesions in the ribs have also been reported in a few patients. Cherubism may have an impact on teeth development. The arrangement of primary teeth can be disturbed and disruption of the secondary dentition can include absent teeth (mostly molars), rudimentary development of molars, abnormally shaped teeth, partially resorbed roots or delayed and ectopically erupting teeth [55] . In the early stages of the disease, patients may present with lymph node enlargement. Most cases of cherubism regress spontaneously after puberty. Pathological evaluation revealed that cherubism lesions resemble giant cell tumours since they contain many giant cells and mononuclear or stromal cells [55] .
The familial form of cherubism occurs typically as an autosomal dominant trait with mutations in the SH3-domain binding protein 2 (SH3BP2) on chromosome 4p16.3. However, de novo mutations may occur in about half of the patients [56] . The exact proportion of cases caused by de novo mutations is unknown because of variable expressivity and reduced penetrance. SH3BP2 is an adapter protein involved in innate and adaptive immune system signalling through interactions and complex formation with binding and scaffolding proteins. In osteoclasts, SH3BP2 can cause phosphorylation and therefore affect signal pathways [57] . Mutations in this regulator cause uncontrolled bone resorption of the jaw. Sh3bp2KI/KI mice, the cherubism mouse model, suggest that cherubism is an AID since inflammatory lesions develop independently of B or T cell involvement. There are at least two mechanisms that account for the phenotype in these mice: inflammatory reactions caused by macrophages producing large amounts of TNF-a and bone resorption caused by hyperactive osteoclasts through activation of nuclear factor of activated T cells c1 [58] . Cherubism is difficult to treat because patients need follow-up care by a craniofacial team with regular dental, orthodontic and ophthalmologic evaluations. Two patients have been unsuccessfully treated with adalimumab [59, 60] .
Bone dysplasia in monogenic AIDs without identified pivotal inflammatory mediators H syndrome H syndrome (OMIM 602782) is a genodermatosis with hyperpigmentation, hypertrichosis, hepatosplenomegaly, hearing loss, heart anomalies, hypogonadism, short stature, hyperglycaemia/diabetes mellitus, hallux valgus/flexion contractures and systemic autoinflammation with febrile attacks and elevation of acute phase reactants in some patients [61] . It is an autosomal recessive disorder resulting from mutations in the SLC29A3 gene, encoding an equilibrative nucleoside transporter hENT3 expressed in lysosomes and mitochondria.
H syndromerelated bone manifestations present as wide long bones with intramedullar infiltration, metaphyseal flaring, diaphyseal cortical hyperostosis, flattened epiphysis and skull thickening of the calvaria (Fig.  1D) . Homozygous or compound heterozygous missense mutations in SLC29A3 also result in dysosteosclerosis, a form of osteopetrosis characterized by the additional features of platyspondyly, metaphyseal osteosclerosis and redviolet macular atrophy of the skin [62] . The expression of SLC29A3 in osteoclasts and the reduced number of osteoclasts in the bone of affected patients suggests that this protein may impact osteoclast differentiation and function [62] . No specific treatment is known.
Ghosal haematodiaphyseal dysplasia syndrome
Ghosal haematodiaphyseal dysplasia is a rare sclerosing bone disorder characterized by metadiaphyseal dysplasia of the long bones and defective haematopoiesis due to fibrosis or sclerosis of the bone marrow. Radiographically it is characterized by expansion and sclerosis of the diaphysis of the long bones with widening of the medullary cavities and cortical endosteal hyperostosis (Fig. 1F) . The base of the skull is also commonly involved. It is associated with haematological manifestations, including variable degrees of anaemia, thrombocytopenia or pancytopenia and with an elevation of acute phase reactants. Approximately 15 cases of this entity have been reported in the literature so far [63] .
It is inherited in an autosomal recessive pattern due to biallelic mutations in the TBXAS1 gene on chromosome 7q3334, which encodes thromboxane A synthase, an enzyme that produces thromboxane A2. Thromboxane A2 is responsible for platelet aggregation (via arachidonic acid cascade) and also modulates BMD variation by influencing the expression of TNFSF11 and TNFRSF11B, which encode RANKL and osteoprotegerin in osteoblasts, leading to sclerosis. These data and the increased levels of acute phase reactants in the majority patients have led to the proposal that Ghosal dysplasia may be an AID, but further pathophysiological studies are required for confirmation [64] . Steroid treatment has proved to be useful for haematological and bony involvement [65] .
CamuratiEngelman syndrome
CamuratiEngelman syndrome or progressive diaphyseal dysplasia (OMIM 131300) is an autosomal dominant inherited disease caused by mutations in the gene TGFB1, encoding TGF-b1, that leads to premature activation of TGF-b1 [66, 67] . The characteristic feature is progressive hyperostosis of the periosteal and endosteal surfaces of the long bones and sometimes cranial hyperostosis, but the clinical course is very variable. Common radiographic findings include cortical thickening of the diaphysis and symmetrical sclerosis that can extend to include the metaphyses [66] . No specific treatment exists, but glucocorticoid therapy has proven effective in controlling bone pain and radiographic signs in a number of cases.
Conclusion
The spectrum of monogenic AIDs continues to expand, with a growing number of autoinflammatory conditions presenting with bone involvement. As shown in the present review, bone manifestations vary widely among AIDs and include non-infectious osteomyelitis, bone loss, hyperostosis, localized or diffuse bone loss, inflammatory bone erosions and bone dysplastic changes. The association of multiple bone alterations with systemic AIDs supports the paradigm that immune cells are also regulators of bone physiology. Targeting the pivotal inflammatory mediators of different AIDs has shown variable efficacy on bone involvement, indicating the need for further study to unravel to precise pathogenic mechanisms of bone manifestations in AIDs. 
